biotechnology
The Unseen Risk: Why Modern Eugenics is the Next ESG Frontier for Finance
Modern eugenics, cloaked as genetic wellness, poses a systemic risk. For finance and investors, it’s the next frontier of ESG and ethical responsibility.
The Investor’s Paradox: What a “Thrifty Gene” Reveals About Surviving a Bull Market
A biological paradox about a ‘thrifty gene’ offers a powerful lesson for investors on rethinking risk, corporate strategy, and economic health.
The $100 Trillion Silent Pandemic: A Financial Blueprint to Avert Global Economic Collapse
Antimicrobial resistance (AMR) is a $100 trillion threat to the global economy. This article explores a financial blueprint to fix the broken antibiotic market.